ZMapp Approval Status
- FDA approved: No
- Brand name: ZMapp
- Company: Mapp Biopharmaceutical, Inc.
- Treatment for: Ebola Virus Disease
ZMapp is a combination of three chimeric monoclonal antibodies manufactured in the Nicotiana benthamiana tobacco plant. It has been used in the experimental treatment of Ebola virus disease.
Development Status and FDA Approval Process for ZMapp
|Sep 17, 2015||Experimental Ebola Treatment ZMapp is Granted Fast Track Status by the FDA|
|Feb 27, 2015||LeafBio Announces Acceptance of Investigational New Drug (IND) Application for Ebola Therapy ZMapp|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.